Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials DOI Creative Commons
Patrick Köck,

Andrzej Badek,

Maximilian Meyer

et al.

Child and Adolescent Psychiatry and Mental Health, Journal Year: 2024, Volume and Issue: 18(1)

Published: Dec. 18, 2024

Abstract Background Cannabinoids have been of increasing interest mainly due to their putative efficacy in a wide array psychiatric, psychosomatic, and neurological conditions. Aims This systematic review aims synthesize results from randomized placebo-controlled trials regarding the dosage cannabinoids as therapeutics psychiatric disorders children, adolescents, young adults. Methods All publications up June 30th, 2024, were included PubMed Embase. Eligibility criteria accordance with PRISMA-guidelines was applied. RCTs providing pre- post-treatment parameters on cannabinoid therapies for mental comparison controls an age range 0 25 years included. Effect sizes calculated Hedges’ g primary outcomes, multilevel random-effects meta-analysis conducted account dependent outcomes same study populations. Results We identified 7603 records, which 8 independent clinical (reported 9 publications) met pre-established eligibility criteria, comprising 474 unique participants (245 treatment, 229 control). Analysis 13 (of 7 trials) revealed modest positive overall effect symptom improvement or normalization brain physiology (Hedges’ = 0.308, 95% CI: 0.167, 0.448). Autism spectrum disorder studies showed most consistent evidence (g 0.264, 0.107, 0.421), while other conditions wider confidence intervals. Age-stratified analysis that adult populations (mean 23.3 years, n 5 outcomes) demonstrated higher 0.463, SD 0.402) compared pediatric 11.8 outcomes; 0.318, 0.212). Whole plant preparations 0.328, 0.083, 0.573) pharmaceutical 0.292, 0.069, 0.515) comparable effects. CBD dosages ranged 17.5 mg 600 per day, no significant correlation between size (ρ -0.014, p 0.963). Mild moderate side effects reported, but serious adverse events. Risk bias assessment low ( 3) high 5). Conclusion While effects, particularly autism disorders, current remains insufficient broadly recommend treating youth Larger, controlled standardized are needed establish definitive recommendations.

Language: Английский

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans DOI Creative Commons
Dolly Andrea Caicedo, Clara Pérez‐Mañá, Magı́ Farré

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 319 - 319

Published: March 1, 2025

Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals therapeutic indications, there are challenges minimizing risks interactions between cannabis-based products, prescription drugs, other approved substances of abuse. Thus, identifying enzymes metabolizing cannabinoid drugs their relationship crucial for understanding potential effects simultaneous use. This article offers a comprehensive review pharmacokinetic as well It also compiles existing evidence these describes clinical outcomes associated inhibition or induction various enzymes.

Language: Английский

Citations

1
Oral cannabidiol did not impair learning and memory in healthy adults DOI Creative Commons

Hanna H. Gebregzi,

Joanna S. Zeiger,

Jeffrey P. Smith

et al.

Journal of Cannabis Research, Journal Year: 2025, Volume and Issue: 7(1)

Published: Jan. 23, 2025

Abstract Background The effect of oral Cannabidiol (CBD) on interference during learning and memory (L&M) in healthy human volunteers has not been studied. Method A two-arm crossover, randomized, double-blind, placebo-controlled trial was conducted at Colorado State University Pueblo (CSU Pueblo) to evaluate the effects 246 mg CBD L&M adults. Among 57 enrolled, 35 were included analyses. For assessment L&M, Montreal Cognitive Assessment (MOCA) used verbal baseline cognitive function; RAVLT-R tests (List List B recalls, Proactive Retroactive Interference ratios, Forgetting Speed ratio) declarative memory; total prose recall logical memory. Linear Mixed Models with Bonferroni Corrections compare results between primary outcomes (CBD vs. placebo) secondary demographic outcomes, a two-tailed statistical significance P < 0.05. Results administration did affect any dependent variables measured compared placebo group. There no THC, history use, or sex CBD’s modulation L&M. However, highly significant interaction treatment groups age subjects observed for PI ratio ( = 0.008; n 35). Conclusions this study suggest that alone does significantly impair might influence related proactive Future research involving larger group older adults is needed confirm potential effect. Trial registration approved by CSU IRB, accordance Declaration Helsinki, registered ClinicalTrials.gov (NCT06074172).

Language: Английский

Citations

0
Hippocampal Apoptosis: Molecular Mechanisms Triggered by Toxic Cannabinoid Exposure: A Narrative Review DOI
Habibeh Mashayekhi‐Sardoo,

Mahdiyeh Hedayati-Moghadam,

Yousef Baghcheghi

et al.

NeuroToxicology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
The association between cannabis use and suicidal intensity in psychiatric inpatients DOI
Adeolu Funso Oladunjoye, Alan C. Swann,

Thomas Kosten

et al.

American Journal on Addictions, Journal Year: 2025, Volume and Issue: unknown

Published: May 10, 2025

Abstract Background Over the past 15 years, most states have legalized medical use of cannabis. Since then, daily nearly tripled while number adults dying by suicide increased 31%. Key studies found a greater suicidal intensity associated with cannabis (CU) in adolescents. Adult associations been understudied. The purpose this study was to evaluate between CU and ideation (SII) adults. Methods We examined 530 psychiatric inpatients ages 18 above using Columbia‐Suicide Severity Rating Scale Alcohol, Smoking Substance Involvement Screening Test for CU. conducted path analysis model moderating mediating factors, including comorbidity, emotional regulation, psychological flexibility, polygenic risk scores externalization, CU, suicide. Results Sixteen percent participants had no suicidality, 34.3% reported ideation, 49.6% prior attempt. be lower SII females ( p = .026) but not males .525), flexibility .049) .628). Conclusions among inpatients, sex‐specific patterns potential mediation flexibility. Further exploring specific amounts, duration use, time frames during adolescence adulthood may provide insights into its risks, especially as legalization expands. Scientific significance Patterns current increase understanding mechanisms predicting adult male inpatients.

Language: Английский

Citations

0
Cannabinoid CB1 receptor-sensitive neurodevelopmental processes and trajectories DOI Creative Commons
Kuei Y. Tseng,

Hanna M. Molla

Molecular Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: May 19, 2025

Abstract As high-potency cannabis (with high Δ 9 -Tetrahydrocannabinol content) becomes easily accessible and widespread, it is of extreme importance for public health that a scientific platform used to implement practical guidelines, particularly at-risk populations. Many reviews have been written in the past decade summarizing impact developing brain. One critical concept frequently mentioned but not discussed detail whether there are sensitive neurodevelopmental events driving age-specific sensitivity cannabis, those mediated by cannabinoid type 1 receptor signaling. By integrating available data from humans animal models, goal present expert review article provide mechanistic overview on how exposure during periods neural circuit plasticity development can result lasting consequences. Here we frontal cortex as proxy align trajectory brain system between rodents. Both strengths limitations studies effects cannabinoids were using developmental framework which adaptations considered. Such an approach needed key variables through lifespan, turn will valuable insights applicable human defining underpinning mechanisms changes childhood adolescence, thereafter young adulthood.

Language: Английский

Citations

0
Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence DOI Creative Commons
Ricardo J. Rodrigues, Joana M. Marques, Attila Köfalvi

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(22), P. 1875 - 1875

Published: Nov. 13, 2024

The endocannabinoid signalling system (ECS) plays a critical role from the very beginning of embryogenesis. Accordingly, ECS is engaged early on in nervous development, starting neurulation, supported by identification components—both receptors and enzymes controlling metabolism—at these stages. In particular, regarding brain, involved tightly regulated sequence events that comprise brain neurogenesis to neuronal migration, morphological guidance for connectivity, synaptic circuitry refinement. importance this broad across various development processes further underscored growing understanding consequences cannabis exposure at different developmental Despite considerable knowledge we have significant gaps our remain, particularly long-term impact underlying mechanisms This review provides an overview current state throughout embryogenesis adulthood, discusses exposure, especially during adolescence—a period maturation refinement coinciding with increased risk use.

Language: Английский

Citations

3
Associations Between Mesolimbic Connectivity, and Alcohol Use from Adolescence to Adulthood DOI Creative Commons
Angelica M. Morales, Scott A. Jones, Bruce A. Carlson

et al.

Developmental Cognitive Neuroscience, Journal Year: 2024, Volume and Issue: 70, P. 101478 - 101478

Published: Nov. 16, 2024

Dopaminergic projections from the ventral tegmental area (VTA) to limbic regions play a key role in initiation and maintenance of substance use; however, relationship between mesolimbic resting-state functional connectivity (RSFC) alcohol use during development remains unclear. We examined associations VTA RSFC subcortical structures 796 participants (12-21 years old at baseline, 51 % female) across 9 waves longitudinal data National Consortium on Alcohol Neurodevelopment Adolescence. Linear mixed effects models included interactions age, sex, use, best fitting were selected using log-likelihood ratio tests. Results demonstrated positive association nucleus accumbens. Age was associated with amygdala hippocampus, an age-by-alcohol interaction VTA-globus pallidus driven by adolescence, but not adulthood. On average, male exhibited greater amygdala, accumbens, caudate, globus pallidus, thalamus. Differences related alcohol, may inform our understanding neurobiological risk resilience for other psychiatric disorders.

Language: Английский

Citations

2
The endocannabinoid system in the brain undergoes long-lasting changes following neuropathic pain DOI Creative Commons
Ming Zhang, Tao Wang, Fancheng Meng

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(12), P. 111409 - 111409

Published: Nov. 22, 2024

Language: Английский

Citations

1
Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials DOI Creative Commons
Patrick Köck,

Andrzej Badek,

Maximilian Meyer

et al.

Child and Adolescent Psychiatry and Mental Health, Journal Year: 2024, Volume and Issue: 18(1)

Published: Dec. 18, 2024

Abstract Background Cannabinoids have been of increasing interest mainly due to their putative efficacy in a wide array psychiatric, psychosomatic, and neurological conditions. Aims This systematic review aims synthesize results from randomized placebo-controlled trials regarding the dosage cannabinoids as therapeutics psychiatric disorders children, adolescents, young adults. Methods All publications up June 30th, 2024, were included PubMed Embase. Eligibility criteria accordance with PRISMA-guidelines was applied. RCTs providing pre- post-treatment parameters on cannabinoid therapies for mental comparison controls an age range 0 25 years included. Effect sizes calculated Hedges’ g primary outcomes, multilevel random-effects meta-analysis conducted account dependent outcomes same study populations. Results We identified 7603 records, which 8 independent clinical (reported 9 publications) met pre-established eligibility criteria, comprising 474 unique participants (245 treatment, 229 control). Analysis 13 (of 7 trials) revealed modest positive overall effect symptom improvement or normalization brain physiology (Hedges’ = 0.308, 95% CI: 0.167, 0.448). Autism spectrum disorder studies showed most consistent evidence (g 0.264, 0.107, 0.421), while other conditions wider confidence intervals. Age-stratified analysis that adult populations (mean 23.3 years, n 5 outcomes) demonstrated higher 0.463, SD 0.402) compared pediatric 11.8 outcomes; 0.318, 0.212). Whole plant preparations 0.328, 0.083, 0.573) pharmaceutical 0.292, 0.069, 0.515) comparable effects. CBD dosages ranged 17.5 mg 600 per day, no significant correlation between size (ρ -0.014, p 0.963). Mild moderate side effects reported, but serious adverse events. Risk bias assessment low ( 3) high 5). Conclusion While effects, particularly autism disorders, current remains insufficient broadly recommend treating youth Larger, controlled standardized are needed establish definitive recommendations.

Language: Английский

Citations

0